Global Chemotherapy-induced Thrombocytopenia Therapeutics Market to Surpass US$ 1,656.0 Million by 2027, Says Coherent Market Insights (CMI)

SEATTLE–(BUSINESS WIRE)–#ChemotherapyinducedTherapy–According to Coherent Market Insights, the global chemotherapy-induced thrombocytopenia therapeutics market is estimated to be valued at US$ 1,168.4 million in 2020 and is expected to exhibit a CAGR of 4.5% during the forecast period (2020-2027).

Key Trends and Analysis of the Global Chemotherapy-induced Thrombocytopenia Therapeutics Market:

Key trends in the market include rising incidence of cancer cases, rising research activities by the market players, increasing number of chemotherapy procedures, and rising adoption of collaboration and acquisition strategies by the market players.

The increasing incidence of cancer is expected to increase the number of chemotherapy procedures leading to the chemotherapy-induced thrombocytopenia, which is further expected to drive the market growth over the forecast period. For instance, according to the World Cancer Research Fund International’s report in 2018, lung cancer was ranked at first position in the total number of cancer cases worldwide, accounting for 2,093,876 new lung cancer cases worldwide in 2018. Moreover, according to the same source, breast cancer accounted for second position and new breast cancer cases reported globally in 2018 was 2,088,849.

Rising research activities by the market players to develop novel treatment for chemotherapy-induced thrombocytopenia is expected to drive the global chemotherapy-induced thrombocytopenia therapeutics market growth over the forecast period. For instance, in June 2019, Jiangsu HengRui Medicine Co., Ltd., initiated the Phase III study, in order to evaluate the efficacy and safety of Hetrombopag in patients with chemotherapy-induced thrombocytopenia receiving chemotherapy for the treatment of solid tumors and lymphomas. The study is expected to complete in December 2020.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4332

Rising number of chemotherapy procedures is increasing the number of chemotherapy-induced thrombocytopenia, thereby driving the market growth. For instance, according to the Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, November 2020, stated that around 650,000 cancer patients in the U.S. receive chemotherapy in an outpatient oncology clinic, annually.

Key Market Takeaways:

The global chemotherapy-induced thrombocytopenia therapeutics market is expected to exhibit a CAGR of 4.5% during the forecast period (2020-2027), owing to rising adoption of inorganic growth strategies such as acquisitions and collaborations by the market players. For instance, in November 2019, Swedish Orphan Biovitrum AB acquired Dova Pharmaceuticals, Inc., a company developing therapeutics for the treatment of thrombocytopenia.

Among regions, North America is expected to hold a dominant position in the global chemotherapy-induced thrombocytopenia therapeutics market over the forecast period, owing to increasing rising cases of cancer in the region. For instance, according to the American Cancer Society, in 2017, around 252,710 new cases of invasive breast cancer were diagnosed among women and 2,470 cases in men in U.S. Also according the same source, nearly 63,410 cases of in situ breast carcinoma were diagnosed among women in the U.S. in 2017.

Competitive Landscape:

Key players operating in the global chemotherapy-induced thrombocytopenia therapeutics market include Amgen Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., Janssen Global Services, LLC (Johnson & Johnson), Partner Therapeutics, Inc., Mission Pharmacal Company, Myelo Therapeutics GmbH, Jiangsu HengRui Medicine Co., Ltd., and Dova Pharmaceuticals, Inc. (Swedish Orphan Biovitrum AB)

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4332

Market Segmentation:

 

By Drug Class:

• Thrombopoietin Receptor Agonists
• Thrombopoietic Agents
• Others

    By Route of Administration:

• Oral
• Injectable

     By Distribution Channel:

• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacies

     By Region:

• North America

• By Country
  • U.S.
  • Canada

• Latin America

• By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America

• Europe

• By Country:
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe

• Asia Pacific

• By Country:
  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific

• Middle East

• By Country:
  • GCC
  • Israel
  • Rest of Middle East

• Africa

• By Country/Region:
  • South Africa
  • Central Africa
  • North Africa

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.

Contacts

Mr. Shah

Senior Client Partner – Business Development

Coherent Market Insights

Phone:
US: +1-206-701-6702

UK: +44-020-8133-4027

Japan: +81-050-5539-1737

India: +91-848-285-0837

Email: [email protected]
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter